Impaired maturation and altered regulatory function of plasmacytoid dendritic cells in multiple sclerosis - PubMed

Affiliations

• PMID: 16513684
• DOI: 10.1093/brain/awl043

Impaired maturation and altered regulatory function of plasmacytoid dendritic cells in multiple sclerosis

Mariusz Stasiolek et al. Brain. 2006 May.

Abstract

Plasmacytoid dendritic cells (pDCs) represent a DC subtype that exerts divergent functions in innate and adoptive immunity including the immediate reaction to microbial factors and the induction of immunoregulatory responses. It is thought that different DC subtypes may be critically involved in the pathogenesis of multiple sclerosis (MS). In our study we assessed the phenotype, maturation and functional properties of peripheral blood pDCs from 35 clinically stable, untreated multiple sclerosis patients, 30 healthy controls and 9 patients with pneumonia, which was used as a non-specific inflammatory condition (NIC). Ex vivo expression of CD86 and 4-1BBL was significantly lower on pDCs from multiple sclerosis patients than from controls and patients with NIC (22 versus 47 versus 41% and 12 versus 35 versus 32%, respectively). When stimulated with IL-3 and CD40L, pDCs of multiple sclerosis patients showed inefficient maturation as demonstrated by significantly lower or delayed upregulation of CD86, 4-1BBL, CD40 and CD83. Additionally, in multiple sclerosis, stimulation of pDCs by unmethylated cytosine-phosphate-guanosine oligodeoxynucleotides (CpG ODN) resulted in a significantly lower interferon (IFN) alpha secretion than in controls. In multiple sclerosis, but not in controls, pDCs failed to upregulate proliferative responses and IFN-gamma secretion of autologous peripheral blood mononuclear cells (PBMC) in a co-culture system. Moreover, depletion of pDCs in multiple sclerosis patients, but not in controls, had no effect on generation of CD4+Foxp3+ regulatory T cells. We also provide data showing that glatiramer acetate (GA) treatment partially restores phenotype and function of pDCs in multiple sclerosis patients. These findings suggest functional abnormalities of pDCs in these patients, which might be of importance in the understanding of the development of immune dysregulation in this disease.

Similar articles

• An imbalance of two functionally and phenotypically different subsets of plasmacytoid dendritic cells characterizes the dysfunctional immune regulation in multiple sclerosis.

  Schwab N, Zozulya AL, Kieseier BC, Toyka KV, Wiendl H. Schwab N, et al. J Immunol. 2010 May 1;184(9):5368-74. doi: 10.4049/jimmunol.0903662. Epub 2010 Mar 31. J Immunol. 2010. PMID: 20357264

• Monocyte-derived HLA-G acts as a strong inhibitor of autologous CD4 T cell activation and is upregulated by interferon-beta in vitro and in vivo: rationale for the therapy of multiple sclerosis.

  Mitsdoerffer M, Schreiner B, Kieseier BC, Neuhaus O, Dichgans J, Hartung HP, Weller M, Wiendl H. Mitsdoerffer M, et al. J Neuroimmunol. 2005 Feb;159(1-2):155-64. doi: 10.1016/j.jneuroim.2004.09.016. Epub 2004 Dec 28. J Neuroimmunol. 2005. PMID: 15652415

• Altered maturation of circulating dendritic cells in primary progressive MS patients.

  López C, Comabella M, Al-zayat H, Tintoré M, Montalban X. López C, et al. J Neuroimmunol. 2006 Jun;175(1-2):183-91. doi: 10.1016/j.jneuroim.2006.03.010. Epub 2006 May 15. J Neuroimmunol. 2006. PMID: 16698091

• Trafficking properties of plasmacytoid dendritic cells in health and disease.

  Sozzani S, Vermi W, Del Prete A, Facchetti F. Sozzani S, et al. Trends Immunol. 2010 Jul;31(7):270-7. doi: 10.1016/j.it.2010.05.004. Epub 2010 Jun 25. Trends Immunol. 2010. PMID: 20579936 Review.

• Dendritic cells in multiple sclerosis: key players in the immunopathogenesis, key players for new cellular immunotherapies?

  Nuyts AH, Lee WP, Bashir-Dar R, Berneman ZN, Cools N. Nuyts AH, et al. Mult Scler. 2013 Jul;19(8):995-1002. doi: 10.1177/1352458512473189. Epub 2013 Jan 31. Mult Scler. 2013. PMID: 23369893 Review.

Cited by

• Glatiramer acetate triggers PI3Kδ/Akt and MEK/ERK pathways to induce IL-1 receptor antagonist in human monocytes.

  Carpintero R, Brandt KJ, Gruaz L, Molnarfi N, Lalive PH, Burger D. Carpintero R, et al. Proc Natl Acad Sci U S A. 2010 Oct 12;107(41):17692-7. doi: 10.1073/pnas.1009443107. Epub 2010 Sep 27. Proc Natl Acad Sci U S A. 2010. PMID: 20876102 Free PMC article.

• Mechanisms underlying the beneficial effects of physical exercise on multiple sclerosis: focus on immune cells.

  Zong B, Yu F, Zhang X, Zhao W, Li S, Li L. Zong B, et al. Front Immunol. 2023 Sep 29;14:1260663. doi: 10.3389/fimmu.2023.1260663. eCollection 2023. Front Immunol. 2023. PMID: 37841264 Free PMC article. Review.

• Plasmacytoid dendritic cells of the gut: relevance to immunity and pathology.

  Lombardi VC, Khaiboullina SF. Lombardi VC, et al. Clin Immunol. 2014 Jul;153(1):165-77. doi: 10.1016/j.clim.2014.04.007. Epub 2014 Apr 24. Clin Immunol. 2014. PMID: 24769378 Free PMC article. Review.

• Oral Cladribine Impairs Intermediate, but Not Conventional, Monocyte Transmigration in Multiple Sclerosis Patients across a Model Blood-Brain Barrier.

  Lin LY, Juillard P, Hawke S, Marsh-Wakefield F, Grau GE. Lin LY, et al. Int J Mol Sci. 2023 Mar 30;24(7):6487. doi: 10.3390/ijms24076487. Int J Mol Sci. 2023. PMID: 37047460 Free PMC article.

• Long-term decrease in VLA-4 expression and functional impairment of dendritic cells during natalizumab therapy in patients with multiple sclerosis.

  de Andrés C, Teijeiro R, Alonso B, Sánchez-Madrid F, Martínez ML, Guzmán de Villoria J, Fernández-Cruz E, Sánchez-Ramón S. de Andrés C, et al. PLoS One. 2012;7(4):e34103. doi: 10.1371/journal.pone.0034103. Epub 2012 Apr 4. PLoS One. 2012. PMID: 22496780 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Silverchair Information Systems

• Research Materials

  • NCI CPTC Antibody Characterization Program